This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

32/100

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

To the Editor: We have recently highlighted the potential pitfalls of amyloid-beta (Aβ) PET, suggesting that both Aβ and tau assessments are necessary to relate clinical symptoms to Alzheimer disease (AD) pathology.1 Herein, we would like to present 3 additional cases related to the clinical practice of disease-modifying therapy (DMT) for AD. These results from tau assessments indicate that their symptoms are irrelevant to AD pathology, even if the Aβ biomarker is positive. Meanwhile, based on the phase 3 trial results,5,6 lecanemab and donanemab are currently designed to be used in patients who exhibit mild cognitive impairment or mild dementia due to AD pathology. We strongly suggest that both Aβ and tau assessments are important to relate clinical symptoms to AD pathology, and are desired to ensure the expected use and evaluation of DMT.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ishibashi, K., Kurihara, M., & Ihara, R. (2025). Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases. Clinical Nuclear Medicine. https://doi.org/10.1097/rlu.0000000000005842

Vancouver

Ishibashi K, Kurihara M, Ihara R. Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases. Clinical Nuclear Medicine. 2025. doi:10.1097/rlu.0000000000005842. PMID: 40108731.

BibTeX

@article{ishibashi2025-40108731,
  author  = {Ishibashi, Kenji and Kurihara, Masanori and Ihara, Ryoko},
  title   = {{Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases}},
  journal = {Clinical Nuclear Medicine},
  year    = {2025},
  doi     = {10.1097/rlu.0000000000005842},
  pmid    = {40108731},
  url     = {https://doi.org/10.1097/rlu.0000000000005842}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

To the Editor: We have recently highlighted the potential pitfalls of amyloid-beta (Aβ) PET, suggesting that both Aβ and tau assessments are necessary to relate clinical symptoms to Alzheimer disease (AD) pathology.1 Herein, we would like to present 3 additional cases related to the clinical practice of disease-modifying therapy (DMT) for AD.
These results from tau assessments indicate that their symptoms are irrelevant to AD pathology, even if the Aβ biomarker is positive.
Meanwhile, based on the phase 3 trial results,5,6 lecanemab and donanemab are currently designed to be used in patients who exhibit mild cognitive impairment or mild dementia due to AD pathology.
We strongly suggest that both Aβ and tau assessments are important to relate clinical symptoms to AD pathology, and are desired to ensure the expected use and evaluation of DMT.

Why it matters

Through three real-world cases, the authors argue that both amyloid-beta and tau assessments are needed to confirm that symptoms are due to Alzheimer disease pathology before starting disease-modifying therapy. They suggest this matters for ensuring appropriate use of lecanemab and donanemab, which are designed for mild cognitive impairment or mild dementia due to AD pathology.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Study designclinical trial
Evidence strengthLow

How this study scored 32/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Clinical Nuclear Medicine)
Journal's citation record	1 / 4	Clinical Nuclear Medicine: journal h-index 90 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 2 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.7 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Ryoko Ihara: h-index 20 (OpenAlex, whole career)
Institution's track record	0 / 3	Tokyo Metropolitan Institute of Gerontology: institution h-index 266 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40108731)
Free to read	2 / 2	Free to read
Total	32 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments

Also tagged “phosphorylated”

733 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 733 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →